within Pharmacolibrary.Drugs.ATC.C;

model C08CA07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.13499999999999998,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Nisoldipine is a second-generation dihydropyridine calcium channel blocker used primarily to treat hypertension and angina pectoris. It works by inhibiting calcium influx into vascular smooth muscle and cardiac muscle, resulting in vasodilation and decreased blood pressure. Nisoldipine is approved for clinical use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following oral administration.</p><h4>References</h4><ol><li><p>Bajcetic, M, et al., &amp; Böger, RH (2007). Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. <i>Journal of clinical pharmacology</i> 47(3) 295–304. DOI:<a href=&quot;https://doi.org/10.1177/0091270006297225&quot;>10.1177/0091270006297225</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17322141/&quot;>https://pubmed.ncbi.nlm.nih.gov/17322141</a></p></li><li><p>van Harten, J, et al., &amp; Breimer, DD (1989). The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration. <i>British journal of clinical pharmacology</i> 27(5) 581–586. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1989.tb03420.x&quot;>10.1111/j.1365-2125.1989.tb03420.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2757881/&quot;>https://pubmed.ncbi.nlm.nih.gov/2757881</a></p></li><li><p>Boelaert, J, et al., &amp; Bogaert, MG (1988). Pharmacokinetics of nisoldipine in renal dysfunction. <i>European journal of clinical pharmacology</i> 34(2) 207–209. DOI:<a href=&quot;https://doi.org/10.1007/BF00614560&quot;>10.1007/BF00614560</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3383992/&quot;>https://pubmed.ncbi.nlm.nih.gov/3383992</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C08CA07;
